Brazilian translation, cross-cultural adaptation and validation of the MG Composite scale and Quantitative Myasthenia gravis testing form: a multicentric study protocol.
Oliveira, Ezequiel Fernandes; Urbano, Jessica Julioti; Santos, Israel Reis; Silva, Anderson Soares; Guimarães, Letícia Lopes; Peixoto, Roger André Oliveira; Perez, Eduardo de Araujo; Bosio, Paulo Cesar; Polaro, Melissa Nunes; Valério, Berenice Cataldo Oliveira; Stirbulov, Roberto; Pereiro, João R.; Nacif, Sergio Roberto; Cavalcante, Valéria; Oliveira, Acary Souza Bulle; Oliveira, Claudia Santos; Oliveira, Luis Vicente Franco
Abstract
Introduction: Myasthenia gravis (MG) is a chronic and inflammatory disease characterized by progressive weakness of the skeletal muscles due to changes in the synaptic junctions between nerves and muscle fibres. Typically, patients have a history of progressive weakness and fatigue in skeletal muscles, which occurs during sustained or repeated activities and improves after rest. Scoring systems to assess the degree of disease severity are commonly used in clinical drug trials. Further, specific instruments to assess health-related quality of life (HRQOL) have been designed to measure self-perception of symptoms and wellness during the disease or after disease treatment. HRQOL is an important component of patient evaluation, as some individuals can tolerate severe impairment and disability, while others may be very unhappy even with less severe symptom profiles. The objective of the proposed study is to translate and perform a cultural adaptation and validation of two specific instruments for assessing the clinical course of patients with MG. These instruments include the Quantitative Test for Myasthenia gravis (QMG) and Myasthenia gravis Composite Scale (MGC). Methods and analyses: The study design will follow a multi-method approach, and will be conducted in three stages consisting of translation, cultural adaptation, and validation of the QMG and MGC for Brazilian Portuguese patients. This multi-step process will consider aspects of construct and predictive validity as well as reliability and structure of the instrument. The entire process will follow the procedures proposed and developed in other linguistic and social-cultural contexts based on previous studies. Ethics: This study has received approval from the Human Research Ethics Committee of Nove de Julho University (Brazil) under process no. 360.488 based on the Helsinki declaration and is registered with the World Health Organization (WHO) under Universal Trial Number (UTN) U1111-1147-7853 and the Brazilian Registry of Clinical Trials (REBEC) RBR -7ckpdd.
Keywords
References
1 - Drachman D. Myasthenia gravis. In: Rose N, Mackay I. The autoimmune diseases. 3rd ed. San Diego: Academic Press, 1998:637–62.
2 - Tzartos SJ, Barkas T, Cung MT, Mamalaki A, Marraud M, Orlewski P, et al. Anatomy of the antigenic structure of a large membrane autoantigen, the muscle-type nicotinic acetylcholine receptor. Immunol Rev. 1998;163:89–120.
3 - Carr AS, Cardwell CR, McCarron PO, McConville J. A systematic review of population based epidemiological studies in Myasthenia Gravis. BMC Neurology. 2010;10:1-9.
4 - Mao ZF, Mo XA, Qin C, Lai YR, Hartman TC. Course and prognosis of myasthenia gravis: a systematic review. Eur J Neurol. 2010;17:913-921.
5 - Jaretzki A 3rd, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology. 2000;55(1):16–23.
6 - AAM Quality Assurance Committee. Literature review of the usefulness of repetitive nerve stimulation and single fiber EMG in the electrodiagnostic evaluation of patients with suspected myasthenia gravis or Lambert–Eaton myasthenic syndrome. Muscle Nerve. 2001;24(9):1239–1247.
7 - Tindall RS, Rollins JA, Phillips JT, Greenlee RG, Wells L, Belendiuk G. Preliminary results of a double-blind, randomized, placebo controlled trial of cyclosporine in myasthenia gravis. N Engl J Med. 1987;316(12):719–24.
8 - Tindall RS, Phillips JT, Rollins JA, Wells L, Hall K. A clinical therapeutic trial of cyclosporine in myasthenia gravis. Ann N Y Acad Sci. 1993;681:539–51.
9 - Burns TM1, Grouse CK, Conaway MR, Sanders DB; mg composite and mg-qol15 study group. Construct and concurrent validation of tha MG-QOL15 in the practice setting. Muscle Nerve. 2010;41(2):219-226.
10 - Burns TM1, Conaway M, Sanders DB; MG Composite and MG-QOL15 Study Group. The MG Composite. A valid and reliable outcome measure for myasthenia gravis. Neurology. 2010;74(18):1434-1440.
11 - Ebrahim S. Clinical and public health perspectives and applications of health- related quality of life measurement. Soc Sci Med. 1995;41:1383–1394.
12 - Cella DF, Tulsky DS. Measuring quality of life today: methodological aspects. Oncology. 1990;4:29–38.
13 - Raggi A, Leonardi M, Antozzi C, Confalonieri P, Maggi L, Cornelio F, et al. Concordance between severity of disease, disability and health-related quality of life in Myasthenia gravis. Neurol Sci. 2010;31:41–45.
14 - Leonardi M, Raggi A, Antozzi C, Confalonieri P, Maggi L, Cornelio F, et al. The relationship between health, disability and quality of life in myasthenia gravis: results from an Italian study. J Neurol. 2010;257:98–102.
15 - Morris J, Perez D, McNoe B. The use of quality of life data in clinical practice. Qual Life Res. 1998;7:85-91.
16 - Besinger UA, Toyka KV, Homberg M, Heininger K, Hohlfeld R, Fateh-Moghadam A. Myasthenia gravis: long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity. Neurology. 1983;33(10):1316–21.
17 - Barohn RJ, McIntire D, Herbelin L, Wolfe GI, Nations S, Bryan WW. Reliability testing of the quantitative myasthenia gravis score. Ann N Y Acad Sci. 1998;841:769–72.
18 - Burns TM, Conaway MR, Cutter GR, Sanders DB. The construction of an efficient evaluative instrument for Myasthenia gravis: the MG Composite. Muscle Nerve. 2008;38:1553–1562.
19 - Burns TM, Conaway MR, Sanders DB, and the MG Composite and MG-QOL15 Study Group. The MG Composite: a valid and reliable tool for myasthenia gravis. Neurology. 2010;74:1434–1440.
20 - Guillemin F, Bombardier C, Beaton D. Cross-cultural adaptation of health-related quality of life measures: literature review and proposed guidelines. J Clin Epidemiol.1993;46(12):1417-32.
21 - Guillemin F. Cross-cultural adaptation and validation of health status measures. Scand J Rheumatol. 1995;24(2):61-3.
22 - Reichenheim M, Moraes C. Operacionalização de adaptação transcultural de instrumentos de aferição usados em epidemiologia. Rev Saúde Pública. 2007;41(4):665-73.
23 - Maher C, Latmer J, Costa L. The relevance of cross-cultural adaptation and clinimetrics for physical therapy instruments. Rev Bras Fisioter. 2007;11(4):245- 52.
24 - Beaton D, Bombardier C, Guillemin F, Ferraz M. Guidelines for process of cross-cultural adaptation of selfreport measures. Spine. 2000;(25)24:3186-91.
25 – Mourão AM, Araújo CM, Barbosa LSM, Gomez RS, Burns TM, Lemos SMA, et al. Brazilian cross-cultural translation and adaptation of the "Questionnaire of Life Quality Specific for Myasthenia Gravis - 15 items". Arq. Neuro-Psiquiatr. 2013 Dec; 71(12):955-958.
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email